POH Oxycodone Patch Dosing in Phase 2 Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Later from Avecho Biotechnology
- Phosphagenics Announces Results of TPM/Oxycodone Ph2a Trial
- Receipt of $2.4m R&D Tax Incentive
- December 2013 Appendix 4E - Annual Financial Report
- Enrolments Completed for Phase 2 Acne Treatment Trial
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology